Related Experiment Video
Updated: Jun 17, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Bevacizumab for advanced breast cancer
Shari B Goldfarb1, Tiffany A Traina, Maura N Dickler
1Breast Cancer Medicine Service, Solid Tumor Division, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. goldfars@mskcc.org
Women'S Health (London, England)
|December 17, 2009
Summary
Bevacizumab, an anti-VEGF antibody, shows clinical benefit in metastatic breast cancer. Combination therapy with paclitaxel or docetaxel improves progression-free survival and response rates in first-line treatment.
Area of Science:
- Oncology
- Cancer Biology
- Pharmacology
Background:
- Tumor angiogenesis is crucial for breast cancer progression, invasion, and metastasis.
- Vascular Endothelial Growth Factor (VEGF) is a key regulator of angiogenesis and a target for cancer therapies.
- Bevacizumab is an antibody targeting VEGF, showing efficacy in various solid tumors.
Purpose of the Study:
- To review clinical trials evaluating Bevacizumab for advanced breast cancer treatment.
- To discuss the role of anti-VEGF therapy in breast cancer management.
Main Methods:
- Review of clinical trial data on Bevacizumab in advanced breast cancer.
- Analysis of studies combining Bevacizumab with chemotherapy (paclitaxel or docetaxel).
Main Results:
- Bevacizumab in combination therapy significantly improved progression-free survival.
- Increased response rates were observed in patients receiving Bevacizumab with chemotherapy.
- Bevacizumab demonstrated clinical benefit in first-line treatment of metastatic breast cancer.
Conclusions:
- Bevacizumab is an effective treatment option for advanced breast cancer, particularly in combination regimens.
- Targeting VEGF with Bevacizumab offers a valuable strategy for improving outcomes in metastatic breast cancer patients.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.